These results suggest that bispecific anti-LRP6 antibodies can inhibit the RSPO1-mediated Wnt signaling amplification and downstream events such as tumor cell invasion, with the guide antigen providing cell type specificity and potency enhancement. The gene discussed is RSPO1; the disease is neoplasm.